# Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma

> **NCT00028886** · PHASE3 · UNKNOWN · sponsor: **Commissie Voor Klinisch Toegepast Onderzoek** · enrollment: 450 (estimated)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** cyclophosphamide
- **DRUG:** dexamethasone
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** melphalan
- **DRUG:** thalidomide
- **DRUG:** vincristine sulfate
- **PROCEDURE:** bone marrow ablation with stem cell support
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00028886
- **Lead sponsor:** Commissie Voor Klinisch Toegepast Onderzoek
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2001-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2013-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00028886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00028886, "Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00028886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*